Fineline Cube

Follow:
14437 Articles
Dizal's Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment
CompanyDrug

Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors
CompanyDrug

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors

Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System
CompanyMedical Device

Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System

Suzhou Zelgen Gains NMPA Approval for ZG006 in Small Cell Lung Cancer Study
CompanyDrug

Suzhou Zelgen Gains NMPA Approval for ZG006 in Small Cell Lung Cancer Study

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658

AstraZeneca's Truqap Granted NMPA Approval for Breast Cancer Treatment
CompanyDrug

AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment

"Novo Nordisk's Sogroya Approved for Use in Boao Lecheng Medical Zone
CompanyDrug

Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone

Regeneron's Eylea HD Receives FDA Priority Review for Macular Edema Treatment
CompanyDrug

Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL
CompanyDrug

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment
CompanyDeals

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment
Company

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment

Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China
CompanyDrug

Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China